BioInvent BOVNF Stock
BioInvent Price Chart
BioInvent BOVNF Financial and Trading Overview
| BioInvent stock price | 0.28 USD |
| Previous Close | 0.28 USD |
| Open | 0.36 USD |
| Bid | 0.27 USD x 250000 |
| Ask | 0.3 USD x 500000 |
| Day's Range | 0.36 - 0.36 USD |
| 52 Week Range | 0.28 - 3.29 USD |
| Volume | 2.5K USD |
| Avg. Volume | 236 USD |
| Market Cap | 18.41M USD |
| Beta (5Y Monthly) | 0.129 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.79 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
BOVNF Valuation Measures
| Enterprise Value | N/A |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.026958281 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
BioInvent Stock Price History
| Beta (5Y Monthly) | 0.129 |
| 52-Week Change | -91.49% |
| S&P500 52-Week Change | 13.32% |
| 52 Week High | 3.29 USD |
| 52 Week Low | 0.28 USD |
| 50-Day Moving Average | 2.59 USD |
| 200-Day Moving Average | 3.11 USD |
BOVNF Share Statistics
| Avg. Volume (3 month) | 236 USD |
| Avg. Daily Volume (10-Days) | 1.02K USD |
| Shares Outstanding | 65.8M |
| Float | 31.44M |
| Short Ratio | N/A |
| % Held by Insiders | 10.16% |
| % Held by Institutions | 57.68% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:25 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | September 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -56.70% |
| Return on Equity (ttm) | -110.15% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | 225.00% |
| Gross Profit (ttm) | N/A |
| EBITDA | -486302016 USD |
| Net Income Avi to Common (ttm) | N/A |
| Diluted EPS (ttm) | -0.79 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | N/A |
| Total Cash Per Share (mrq) | N/A |
| Total Debt (mrq) | N/A |
| Total Debt/Equity (mrq) | 9.62 USD |
| Current Ratio (mrq) | 2.796 |
| Book Value Per Share (mrq) | 10.379 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | -280654880 USD |
Profile of BioInvent
| Country | United States |
| State | N/A |
| City | Lund |
| Address | The Gamma Building |
| ZIP | 223 70 |
| Phone | 46 4 62 86 85 50 |
| Website | https://www.bioinvent.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 107 |
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin's lymphoma, and solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1/2a clinical trial for the treatment of solid tumors. It has a collaboration with Transgene oncolytic virus platform with BioInvent proprietary antibodies; MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda; CASI Pharmaceuticals to develop BI-1206 in both hematological and solid cancers; AstraZeneca to evaluate BI-1206 in combination with rituximab and Calquence; and XOMA. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.
Q&A For BioInvent Stock
What is a current BOVNF stock price?
BioInvent BOVNF stock price today per share is 0.28 USD.
How to purchase BioInvent stock?
You can buy BOVNF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BioInvent?
The stock symbol or ticker of BioInvent is BOVNF.
Which industry does the BioInvent company belong to?
The BioInvent industry is Biotechnology.
How many shares does BioInvent have in circulation?
The max supply of BioInvent shares is 65.8M.
What is BioInvent Price to Earnings Ratio (PE Ratio)?
BioInvent PE Ratio is now.
What was BioInvent earnings per share over the trailing 12 months (TTM)?
BioInvent EPS is -0.79 USD over the trailing 12 months.
Which sector does the BioInvent company belong to?
The BioInvent sector is Healthcare.
